Form 4: Bristol Myers Squibb Director Acquires DSUs

Bristol Myers Squibb Director Paula A. Price acquired 3,996.367 Deferred Share Units, increasing her beneficial ownership.

Summary

• Paula A. Price, a Director of Bristol-Myers Squibb Co (BMY), acquired 3,996.367 Deferred Share Units (DSUs).
• The transaction occurred on February 1, 2026.
• Each Deferred Share Unit is convertible into one share of common stock upon settlement.
• Settlement of the DSUs occurs when the reporting person ceases to be a director or at a previously specified future date.
• The acquisition price for the DSUs was $55.05 per unit.
• Following this transaction, Paula A. Price beneficially owns a total of 25,498.163 Deferred Share Units.
• The total beneficially owned units include deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, as a director's increased stake, even through compensation, generally reflects confidence in the company's long-term value and strategic direction.

Positives

• A director increasing their stake in the company, even through deferred compensation, can signal confidence in the company's future prospects.
• The acquisition of Deferred Share Units aligns the director's interests more closely with those of the shareholders.

Future Outlook

The filing indicates that Deferred Share Units will be converted into common stock upon settlement, which occurs when the reporting person ceases to be a director or at a future date previously specified by the reporting person, suggesting a long-term alignment with the company's performance.

Industry Context

StockSavvy.ai notes that insider transactions, particularly acquisitions by directors, are often viewed by the market as a positive indicator of management's belief in the company's future. In the pharmaceutical industry, such transactions can reinforce confidence amidst ongoing R&D cycles and regulatory landscapes.

Stakeholder Impact

• Shareholders: The transaction indicates increased alignment of a director's interests with those of shareholders, potentially fostering greater confidence in governance and future performance.
• Employees: No direct impact mentioned, but strong insider confidence can indirectly boost morale.

Next Steps

• The Deferred Share Units will be converted into shares of common stock upon settlement, which will occur when Paula A. Price ceases to be a director or at a future date she previously specified.

Key Dates

Recommendation

While the director's acquisition of Deferred Share Units signals confidence, this is a routine compensation-related transaction and not a significant open-market purchase. It provides a minor positive sentiment but is unlikely to be a standalone catalyst for a strong buy or sell recommendation. Investors should hold and consider this as a small positive data point within a broader investment thesis for Bristol Myers Squibb.

Keywords

BMY, Bristol Myers Squibb, Insider Transaction, Form 4, Director, Deferred Share Units, Equity Compensation, Pharmaceuticals